Herantis Pharma PLC · OMXHEX:HRTIS
Herantis Pharma — TreatER Webcast (November 2020)
12 slides from Herantis Pharma's conference presentation, Nov 18, 2020
Slide 1: CDNF in the First-in-Human Clinical Trial
CDNF in the First-in-Human Clinical Trial 12 months clinical data on the monthly infusions of CDNF directly into a targeted area of the brain of people living with Parkinson’s Magnus Sjögren, Chief Medical Officer at Herantis Pharma Plc. And Professor Per Svenningsson, Principal Investigator, Karoli
Slide 2: 12 Months Secondary Endpoint – Efficacy
CDNF in the First-in-Human clinical trial 12 Months Secondary Endpoint – Efficacy Professor Per Svenningsson, Principal Investigator 13 11/20/20 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.
Slide 3: Efficacy Assessment During the Clinical Trial
Efficacy Assessment During the Clinical Trial Efficacy Was Assessed At Screening, Prior To Treatment Start And During The Treatment Period: • Patient home diary: every half hour for three days before every infusion visit ○ ”ON” without dyskinesias, “ON” with non-troublesome dyskinesias, “ON” with tr
Slide 4: Other Exploratory Efficacy Assessments
Other Exploratory Efficacy Assessments • DAT-PET imaging for density of dopaminergic neurons in different brain areas • Analysis of blood serum and cerebrospinal fluid for ○ CDNF levels ○ Alpha-synuclein levels ○ Identification of new biomarkers in Parkinson’s disease affected by CDNF • Parkinson’s
Slide 5: UPDRS Part III (Off) Absolute Scores
UPDRS Part III (Off) Absolute Scores All CDNF-Treated Patients: achieved definition of ‘minimal clinically important difference’ in UPDRS part 3 (motor score); 1.4-2.6 point improvement (pooled data) © 2014-2020 HERANTIS PHARMA Plc. All rights reserved. 16
Slide 6: Example of A Responder
Example of A Responder Patient Data: ○ Hoehn & Yahr stage: 2 ○ Disease duration: 10 years (from first motor symptoms) ○ UPDRS part III at screening → OFF: 25 improvement improvement → ON: 11 ○ Levodopa response: 74% ○ OFF time per day: 5.8 hours Received 6 placebo infusions followed by 2 low and 4 m
Slide 7: Parkinson's Kinetigraph (PKG): preliminary analysis
Parkinson’s KinetigraphTM (PKGTM): preliminary analysis BKS is the Bradykinesia Score, Adjusted for the Levodopa Equivalent Dose (LED) # treatment effect in separate time points Vehicle vs CDNF mid-dose © 2014-2020 HERANTIS PHARMA Plc. All rights reserved. 18
Slide 8: DAT-PET Scanning Examples
DAT-PET Scanning Examples Example of decreased signal: patient on placebo Baseline 6 months Example of increased signal: patient on mid-dose CDNF Baseline 6 months © 2014-2020 HERANTIS PHARMA Plc. All rights reserved. 19
Slide 9: Exploratory Endpoint: Dopamine transporter (DAT) PET in putamen
Exploratory Endpoint: Dopamine transporter (DAT) PET in putamen (the infusion target area) • Mid-dose group (with placebo crossovers) % change average reduces - 3.2% from Extension study start, high-dose increases +7.4% (for high-dose placebo crossovers PET data is not available) • The original mid-
Slide 10: Exploratory Endpoint: CSF alpha-synuclein levels
Exploratory Endpoint: levels of cerebrospinal fluid alpha-synuclein at baseline, 6 months and 12 months TOTAL ALPHA-SYNUCLEIN RATIO OF OLIGOMERIC/TOTAL ALPHA-SYNUCLEIN 1750 60 Placebo Mid-dose High-dose Placebo Mid-dose High-dose Total aSyn in CSF (pg/ml) Oligomeric/Total aSyn 1500 CDNF CDNF CDNF CD
Slide 11: Conclusions
Conclusions The Study Was Designed to Show Safety and Tolerability => Primary endpoint met! The Study Was Not Designed to Show Efficacy: • Too small patient numbers => a lot of noise from single patients and outliers • The advanced PD patient population was not suitable to show effects of neuroprote
Slide 12: Thank you!
Thank you! 24 11/20/20 www.herantis.com © 2014-2020 HERANTIS PHARMA Plc. All rights reserved.